Leo Laboratories

LEO Pharma is a Danish, independent, research-based pharmaceutical company focused primarily on medical dermatology. The requested name "Leo Laboratories" appears to refer to the LEO Pharma group and regional legal entities such as Leo Laboratories Ltd., rather than a separate standalone biotech. The company markets dermatology products globally and has strategic growth brands including Adtralza/Adbry, Anzupgo, and Spevigo, while also advancing late-stage and earlier-stage pipeline programs in inflammatory and rare skin diseases. LEO Pharma is controlled by the LEO Foundation, with Nordic Capital as a co-owner since 2021. Its business combines internal R&D, licensing, and acquisitions to build a specialized dermatology franchise across topical, biologic, and oral therapies.